CAPR Stock Drop: Capricor Therapeutics Clinical Data Leads to 64% Stock Drop and Securities Fraud Class Action for Investors
Bleichmar Fonti & Auld LLP announced that a class action lawsuit has been filed against Capricor Therapeutics regarding alleged securities fraud tied to clinical data for Deramiocel. The complaint alleges that Capricor made false statements concerning its lead product candidate and the integrity of the data supporting its Biologics License Application.
Key figures
- Stock drop percentage
- 64.5%
- Lead plaintiff deadline
- September 28, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.